Edition:
United States

Aethlon Medical Inc (AEMD.OQ)

AEMD.OQ on NASDAQ Stock Exchange Capital Market

1.29USD
4:00pm EDT
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.29
Open
$1.28
Day's High
$1.29
Day's Low
$1.28
Volume
3,722
Avg. Vol
74,951
52-wk High
$3.85
52-wk Low
$0.80

Chart for

About

Aethlon Medical, Inc. is a medical device company focused on creating devices for cancer, infectious disease and other life-threatening conditions. The Company operates through two segments: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities. The Company's... (more)

Overall

Beta: 2.20
Market Cap(Mil.): $21.54
Shares Outstanding(Mil.): 16.70
Dividend: --
Yield (%): --

Financials

  AEMD.OQ Industry Sector
P/E (TTM): -- 35.59 33.60
EPS (TTM): -0.65 -- --
ROI: -202.33 14.13 13.19
ROE: -253.42 16.91 15.00

BRIEF-Aethlon Medical Participates In Informational Meeting With FDA​

* AETHLON MEDICAL SAYS ‍ON MARCH 20, CO PARTICIPATED IN AN INFORMATIONAL MEETING WITH FDA​ - SEC FILING

Mar 21 2018

BRIEF-Aethlon Medical Announces Fiscal 2018 Third Quarter Results

* AETHLON MEDICAL ANNOUNCES FISCAL 2018 THIRD QUARTER RESULTS

Feb 01 2018

BRIEF-Aethlon Medical Says Granted U.S. Patent That Broadens Protection For The Aethlon Hemopurifier

* AETHLON MEDICAL ANNOUNCES ALLOWANCE OF U.S. PATENT THAT BROADENS PROTECTION FOR THE AETHLON HEMOPURIFIER® TO TREAT VIRAL INFECTIONS Source text for Eikon: Further company coverage:

Jan 18 2018

BRIEF-Sabrina Johnson Joins Aethlon Medical's Board Of Directors

* SABRINA MARTUCCI JOHNSON JOINS AETHLON MEDICAL'S BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

Jan 10 2018

BRIEF-Aethlon Medical Names Dr. Charles J. Fisher Chairman Of The Board

* AETHLON MEDICAL NAMES DR. CHARLES J. FISHER CHAIRMAN OF THE BOARD Source text for Eikon: Further company coverage:

Nov 29 2017

BRIEF-Aethlon Medical announces second quarter results

* Aethlon Medical announces fiscal 2018 second quarter results

Nov 02 2017

Competitors

Earnings vs. Estimates